Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation
Identifieur interne : 002C55 ( Main/Exploration ); précédent : 002C54; suivant : 002C56Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation
Auteurs : Steven R. Mostow ; Stephen C. Schoenbaum ; Walter R. Dowdle ; Marion T. Coleman ; Harold S. KayeSource :
- Postgraduate Medical Journal [ 0032-5473 ] ; 1973-03.
English descriptors
- Teeft :
- Adverse reactions, Aichi, Aichi antigen, Aichi vaccine, Aichi vaccines, Antibody response, Antibody responses, Attack rate, Attack rates, Better protection, California retirement community, Commercial polyvalent vaccine, Density gradient centrifugation, Disease control, Dos, Dosage, Dowdle, Georgia state prison, High dose, High dose recipients, High doses, Higher dose level, Higher doses, Hong kong variant, Hong kong virus, Influenza, Influenza vaccine, Influenza vaccines, Large doses, Local reaction, Local reactions, Mostow, Nasal secretions, Nasal washings, Natural disease, Natural infection, Neutralizing activity, Neutralizing substances, Older children, Orange county schools, Plateau effect, Present address, Prevaccination titres, Previous study, Retirement community, School absenteeism, Serologic responses, Sharples, Sharples vaccine, Sharples vaccines, Standard dose, Systemic reaction, Systemic reactions, Unit group, Unit recipients, Unit vaccine, Unit vaccine recipients, Vaccine, Vaccine dose, Vaccine efficacy, Zonal, Zonal centrifugation, Zonal ultracentrifugation.
Abstract
In these studies very high doses (up to 4800 CCA units in adults) of formalin inactivated influenza vaccine purified by density gradient centrifugation were given safely to more than 5000 volunteers drawn from adolescent, middle aged and elderly populations. The relative paucity of reactions, compared with those groups receiving much lower doses of formalin-inactivated vaccine produced by Sharples centrifugation, suggests that reactions are due to non-viral substances rather than to toxic properties of the viruses, and that these substances are removable. Homologous serum HI antibody responses increased with increasing vaccine dosage and there was no plateau effect at the higher dose level. In those groups studied, the appearance of neutralizing activity in post-vaccination nasal washings correlated closely with the higher vaccine doses and higher HI antibody titres. The occurrence of the ‘Hong Kong flu’ epidemic in two of the groups, including over 3000 vaccine recipients, provided a unique opportunity to study the efficacy of the various vaccines used. Only those groups receiving high doses of a Hong Kong-like antigen (A2/Aichi/2/68) enjoyed significant reduction in illness (70%). Furthermore, there was a 90% reduction in the incidence of fever in that group. These results indicate that very large doses of purified influenza vaccine can be given safely. Significant prevention and modification of disease caused by influenza via the vaccine approach is dependent on the administration of large doses of the appropriate antigen.
Url:
DOI: 10.1136/pgmj.49.569.152
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000017
- to stream Istex, to step Curation: 000017
- to stream Istex, to step Checkpoint: 001800
- to stream Main, to step Merge: 002E30
- to stream Main, to step Curation: 002C55
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation</title><author><name sortKey="Mostow, Steven R" sort="Mostow, Steven R" uniqKey="Mostow S" first="Steven R." last="Mostow">Steven R. Mostow</name></author><author><name sortKey="Schoenbaum, Stephen C" sort="Schoenbaum, Stephen C" uniqKey="Schoenbaum S" first="Stephen C." last="Schoenbaum">Stephen C. Schoenbaum</name></author><author><name sortKey="Dowdle, Walter R" sort="Dowdle, Walter R" uniqKey="Dowdle W" first="Walter R." last="Dowdle">Walter R. Dowdle</name></author><author><name sortKey="Coleman, Marion T" sort="Coleman, Marion T" uniqKey="Coleman M" first="Marion T." last="Coleman">Marion T. Coleman</name></author><author><name sortKey="Kaye, Harold S" sort="Kaye, Harold S" uniqKey="Kaye H" first="Harold S." last="Kaye">Harold S. Kaye</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:490E5AD2AB5658AD910010EFFA7F05C8134137A4</idno><date when="1973" year="1973">1973</date><idno type="doi">10.1136/pgmj.49.569.152</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-D3018GMD-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000017</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000017</idno><idno type="wicri:Area/Istex/Curation">000017</idno><idno type="wicri:Area/Istex/Checkpoint">001800</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001800</idno><idno type="wicri:doubleKey">0032-5473:1973:Mostow S:inactivated:vaccines:volunteer</idno><idno type="wicri:Area/Main/Merge">002E30</idno><idno type="wicri:Area/Main/Curation">002C55</idno><idno type="wicri:Area/Main/Exploration">002C55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation</title><author><name sortKey="Mostow, Steven R" sort="Mostow, Steven R" uniqKey="Mostow S" first="Steven R." last="Mostow">Steven R. Mostow</name></author><author><name sortKey="Schoenbaum, Stephen C" sort="Schoenbaum, Stephen C" uniqKey="Schoenbaum S" first="Stephen C." last="Schoenbaum">Stephen C. Schoenbaum</name></author><author><name sortKey="Dowdle, Walter R" sort="Dowdle, Walter R" uniqKey="Dowdle W" first="Walter R." last="Dowdle">Walter R. Dowdle</name></author><author><name sortKey="Coleman, Marion T" sort="Coleman, Marion T" uniqKey="Coleman M" first="Marion T." last="Coleman">Marion T. Coleman</name></author><author><name sortKey="Kaye, Harold S" sort="Kaye, Harold S" uniqKey="Kaye H" first="Harold S." last="Kaye">Harold S. Kaye</name></author></analytic><monogr></monogr><series><title level="j">Postgraduate Medical Journal</title><title level="j" type="abbrev">Postgrad Med J</title><idno type="ISSN">0032-5473</idno><idno type="eISSN">1469-0756</idno><imprint><publisher>The Fellowship of Postgraduate Medicine</publisher><date type="published" when="1973-03">1973-03</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">569</biblScope><biblScope unit="page" from="152">152</biblScope></imprint><idno type="ISSN">0032-5473</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0032-5473</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse reactions</term><term>Aichi</term><term>Aichi antigen</term><term>Aichi vaccine</term><term>Aichi vaccines</term><term>Antibody response</term><term>Antibody responses</term><term>Attack rate</term><term>Attack rates</term><term>Better protection</term><term>California retirement community</term><term>Commercial polyvalent vaccine</term><term>Density gradient centrifugation</term><term>Disease control</term><term>Dos</term><term>Dosage</term><term>Dowdle</term><term>Georgia state prison</term><term>High dose</term><term>High dose recipients</term><term>High doses</term><term>Higher dose level</term><term>Higher doses</term><term>Hong kong variant</term><term>Hong kong virus</term><term>Influenza</term><term>Influenza vaccine</term><term>Influenza vaccines</term><term>Large doses</term><term>Local reaction</term><term>Local reactions</term><term>Mostow</term><term>Nasal secretions</term><term>Nasal washings</term><term>Natural disease</term><term>Natural infection</term><term>Neutralizing activity</term><term>Neutralizing substances</term><term>Older children</term><term>Orange county schools</term><term>Plateau effect</term><term>Present address</term><term>Prevaccination titres</term><term>Previous study</term><term>Retirement community</term><term>School absenteeism</term><term>Serologic responses</term><term>Sharples</term><term>Sharples vaccine</term><term>Sharples vaccines</term><term>Standard dose</term><term>Systemic reaction</term><term>Systemic reactions</term><term>Unit group</term><term>Unit recipients</term><term>Unit vaccine</term><term>Unit vaccine recipients</term><term>Vaccine</term><term>Vaccine dose</term><term>Vaccine efficacy</term><term>Zonal</term><term>Zonal centrifugation</term><term>Zonal ultracentrifugation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In these studies very high doses (up to 4800 CCA units in adults) of formalin inactivated influenza vaccine purified by density gradient centrifugation were given safely to more than 5000 volunteers drawn from adolescent, middle aged and elderly populations. The relative paucity of reactions, compared with those groups receiving much lower doses of formalin-inactivated vaccine produced by Sharples centrifugation, suggests that reactions are due to non-viral substances rather than to toxic properties of the viruses, and that these substances are removable. Homologous serum HI antibody responses increased with increasing vaccine dosage and there was no plateau effect at the higher dose level. In those groups studied, the appearance of neutralizing activity in post-vaccination nasal washings correlated closely with the higher vaccine doses and higher HI antibody titres. The occurrence of the ‘Hong Kong flu’ epidemic in two of the groups, including over 3000 vaccine recipients, provided a unique opportunity to study the efficacy of the various vaccines used. Only those groups receiving high doses of a Hong Kong-like antigen (A2/Aichi/2/68) enjoyed significant reduction in illness (70%). Furthermore, there was a 90% reduction in the incidence of fever in that group. These results indicate that very large doses of purified influenza vaccine can be given safely. Significant prevention and modification of disease caused by influenza via the vaccine approach is dependent on the administration of large doses of the appropriate antigen.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Coleman, Marion T" sort="Coleman, Marion T" uniqKey="Coleman M" first="Marion T." last="Coleman">Marion T. Coleman</name><name sortKey="Dowdle, Walter R" sort="Dowdle, Walter R" uniqKey="Dowdle W" first="Walter R." last="Dowdle">Walter R. Dowdle</name><name sortKey="Kaye, Harold S" sort="Kaye, Harold S" uniqKey="Kaye H" first="Harold S." last="Kaye">Harold S. Kaye</name><name sortKey="Mostow, Steven R" sort="Mostow, Steven R" uniqKey="Mostow S" first="Steven R." last="Mostow">Steven R. Mostow</name><name sortKey="Schoenbaum, Stephen C" sort="Schoenbaum, Stephen C" uniqKey="Schoenbaum S" first="Stephen C." last="Schoenbaum">Stephen C. Schoenbaum</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:490E5AD2AB5658AD910010EFFA7F05C8134137A4
|texte= Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation
}}
| This area was generated with Dilib version V0.6.33. |  |